The therapeutic benefits of allogeneic stem cell transplantation in patients with hematologic disorders are limited by the significant morbidity and mortality of graft-versus-host disease (GVHD). Current agents for the prevention and treatment of GVHD have limited efficacy and often result in toxic side-effects. Mycophenolate mofetil (MMF) is a new immunosuppressant with a selective mechanism of action. When employed following solid organ transplantation, MMF reduces the incidence and severity of acute rejection episodes. By selectively targeting activated lymphocytes, the active metabolite of MMF, mycophenolic acid (MPA), appears to augment the actions of standard immunosuppressant agents without adding overlapping toxicities. Studies of combination regimens that include MMF report that this agent permits a dose reduction of cyclosporine, tacrolimus, or corticosteroid, without increasing the incidence of acute rejection in solid organ transplants. Reports on the efficacy of MMF following stem cell transplantation in animal studies were mixed. However, the use of a non-myeloablative conditioning regimen with a post-graft immunosuppressive regimen of MMF and cyclosporine was able to sustain stable mixed chimeras in 60% to 80% of dogs who received hematopoietic grafts from DLA-identical littermates. MMF has demonstrated activity in preliminary clinical trials for GVHD prophylaxis, and treatment of acute or chronic GVHD. Larger clinical trials are warranted to determine the optimum dose and route of MMF administration for GVHD, as well as the comparative safety and efficacy of MMF-containing regimens. Allogeneic stem cell transplantation (SCT) has significant therapeutic benefits for many patients with hematologic disorders. Unfortunately, the benefits of the stem cell graft are limited by the significant morbidity and mortality of graftversus-host disease (GVHD).
Allogeneic stem cell transplantation (SCT) has significant therapeutic benefits for many patients with hematologic disorders. Unfortunately, the benefits of the stem cell graft are limited by the significant morbidity and mortality of graftversus-host disease (GVHD). 1 In related donor, histocompatible-matched, and unmanipulated allografts, acute GVHD develops in approximately 30% to 60% of SCT recipients; when the donor and recipient are unrelated or histoincompatible, the prevalence is higher, from 40% to 90%. 2, 3 Mortality, as a direct or indirect consequence of acute GVHD, may be as high as 50%. 2 In addition, chronic GVHD develops in 35% to 50% of long-term survivors. 2 Current post-transplantation therapies to prevent or treat GVHD are only partially effective. Furthermore, these immunosuppressive regimens often result in significant toxicities. With cyclosporine therapy, the prevalence of nephrotoxicity can be as high as 75%. 4 Long-term use of glucocorticoids increases the risk of hyperglycemia, infections, avascular necrosis of bone, and osteoporosis. 2, 4 The therapeutic index for methotrexate (MTX) is extremely low, and the occurrence of hyperbilirubinemia, bone marrow suppression, or mucositis is common. 4, 5 There is an obvious need for new immunosuppressive strategies that provide greater control of GVHD with less toxicity. Mycophenolate mofetil (MMF) is an immunosuppressant presently used for the prophylaxis of renal or cardiac allograft rejection. This paper reviews the rationale for clinically testing MMF for the management of GVHD. Topics covered include MMF pharmacodynamics, the immunosuppressant efficacy of MMF in solid organ transplantation, and preclinical and preliminary clinical trial findings of MMF in GVHD models.
The pharmacodynamics of mycophenolate mofetil
Mycophenolate mofetil is an antiproliferative agent that interrupts the late stage of the immune response signaling sequence at the time of DNA synthesis. In vivo, MMF is de-esterified to the active compound, mycophenolic acid (MPA). Mycophenolic acid, which is not a nucleotide analog, noncompetitively and reversibly inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), the ratelimiting enzyme for de novo purine synthesis during cell division. 6 Since proliferating lymphocytes, but not most other cells, rely primarily on the de novo pathway rather than the salvage pathway, MPA provides more selective action than that of many other immunosuppressants. 5 
In vitro, ex vivo, and in vivo studies of MMF mechanisms of action
Studies have established the mechanisms of MMF immunosuppressive effects. When immunosuppressive doses were administered, MPA significantly decreased the intracellular pool of guanosine nucleotides in T and B lymphocytes and promonocytes in peripheral blood. 5, 7 Following in vitro stimulation by mitogens or alloantigens, MMF inhibited the production of antibodies and the generation of cytotoxic T cells. 5, 8 Mycophenolic acid was also shown to decrease glycosylation of adhesion molecules, down-regulating the expression of leukocyte adhesion molecules, which are involved in recruitment of lymphocytes and monocytes to sites of inflammation. 6, 8 The pharmacokinetics of MMF After oral or i.v. administration, MMF is rapidly and completely metabolized to MPA. The mean absolute bioavailability of oral MMF relative to i.v. MMF, based on the area under the curve (AUC) of MPA, is 94%. The AUC of MPA increases in a dose-proportional manner in renal transplant patients receiving multiple oral doses of MMF up to a total daily dosage of 3 g. MPA plasma concentrations in early renal transplant patients (Ͻ40 days post transplant) are approximately 45% to 50% of those levels achieved in healthy volunteers, and 20% to 30% of those achieved in stable renal or cardiac transplant patients. 4 The bioavailability of oral MMF may be compromised in allogeneic SCT patients who develop GVHD with gastrointestinal involvement. 9 A dose of 1 g twice a day administered orally or intravenously is recommended for use in renal transplant patients. A dose of 1.5 g twice a day administered orally or intravenously is recommened for use in cardiac transplant patients. Both oral and i.v. dosing regimens have been used in the prophylaxis and treatment of GVHD. The doses generally used were 1 to 2 g per day.
9-11 Doses as high as 3 g per day have been used in the treatment of GVHD. 12 
Efficacy in solid organ transplantation
Mycophenolate mofetil has been approved in the USA for the prevention of renal allograft rejection, as well as cardiac allograft rejection. It is currently under investigation in liver and other solid organ transplant settings.
The primary basis for US approval of MMF as an adjuvant immunosuppressant agent was the findings of three large multicenter studies in 1493 adult recipients of a cadaveric renal allograft. The ability of MMF (2 g/day or 3 g/day) to control biopsy-proven acute rejection episodes during the first 6 months post transplantation was compared to either azathioprine or a placebo, combined with a maintenance regimen of full-dose cyclosporine and a corticosteroid. 13 The results in all three studies were similar. 14 In a pooled analysis of efficacy, MMF was shown to reduce the incidence, as well as the histologically graded severity of acute rejection episodes by approximately 50%. 13 It also significantly reduced the need for antithymocyte globulin (ATG) to treat severe, corticosteroid-resistant rejection. 13 Use of MMF in cardiac allograft recipients was studied in a multicenter trial of 650 patients randomized to receive MMF 3 g/d, azathioprine, or placebo, in combination with full-dose cyclosporine and a corticosteroid. 15 The 1-year mortality was 45% lower in the MMF treatment group than in the azathioprine treatment group. 15 The improvement in patient survival may be due, at least in part, to the fact that significantly fewer patients in the MMF treatment group required rescue therapy for acute rejection during the first 6 months, reducing the risk of death due to infection or sepsis. 15 A large randomized trial compared the effects of a double therapy regimen of tacrolimus and a corticosteroid to triple therapy with tacrolimus, corticosteroid, and MMF 2 g/d in 200 adult recipients of a primary orthotopic liver transplant. 16 Although patient and graft survival were comparable in both double-drug and triple-drug treatment groups, there was a trend toward a reduced incidence of acute rejection episodes, a reduction in the mean maintenance and cumulative doses of corticosteroids, and better preservation of renal function among patients in the MMF treatment group. 16 
Adverse effects in solid organ transplantation
Most adverse events associated with MMF therapy are dose-related and predominantly affect hematological or GI systems. 6, 17 In the phase III trials for prevention of renal or cardiac allograft rejection, the most commonly reported side-effects were related to gastrointestinal events or bone marrow suppression. 15, [17] [18] [19] [20] Unlike cyclosporine or tacrolimus, MMF therapy is rarely associated with nephrotoxicity, neurotoxicity, or hepatotoxicity. 17 The range of reported gastrointestinal complaints in these clinical trials was 11% to 26% for abdominal pain, 4% to 54% for nausea, 2% to 34% for vomiting, and 13% to 45% complained of diarrhea. 15, [18] [19] [20] More serious but rarer GI adverse events included GI hemorrhage, large-bowel perforation, or pancreatitis. 15, [17] [18] [19] [20] Mild GI adverse events were usually resolved by dividing the daily dose into three or four administrations; more severe GI adverse events required a dose reduction or discontinuation. 17 The most prominent hematologic effect in MMF treatment groups was the occurrence of leukopenia (11% to 35%), but the incidence of anemia (4% to 39%) and thrombocytopenia (3% to 9%) was also increased. 15, [17] [18] [19] [20] Hematologic adverse events generally reversed within a week of discontinuing therapy. 17, 18 As with all potent immunosuppressants, therapy with MMF increases the risk of opportunistic infection and malignancy. In the MMF treatment groups, there was a slight increase in the incidence of viral opportunistic infections, especially those caused by a herpes virus; lymphoproliferative disorders were infrequent and comparable to those seen in other treatment groups.
15,17,19,20

Preclinical trials of MMF for GVHD
The effect of MMF was tested in a fully mismatched murine model of acute GVHD. 21 In this model, therapy with MMF 30 or 60 mg/kg/day alone or in combination with standard-dose cyclosporine did not significantly increase the mean survival time when compared with cyclosporine alone. 21 The investigators speculated that the antiproliferative effect of MMF on rapidly dividing stem cells may have caused bone marrow suppression that impaired hematopoietic engraftment. 21 More promising results were seen in studies utilizing a canine model of GVHD treated with a non-myeloablative conditioning regimen combined with a post-graft immunosuppressive regimen of cyclosporine 30 mg/kg/day plus MMF 20 mg/kg/day. 22, 23 In one study, the conditioning regimen for DLA-identical littermates was a sublethal dose of 200 cGy total body irradiation (TBI). In the control group, intermittently administered MTX 0.4 mg/kg was substituted for MMF in the post-graft regimen. 22 Following bone marrow transplantation, four of five dogs in the cyclosporine/MMF group achieved stable mixed chimeras without acute or chronic GVHD; in the cyclosporine/MTX group, this was achieved in three of six dogs. 22 The following year, these investigators reported results from another canine study of MMF on marrow engraftment. In this trial, random bred dogs received a conditioning regimen of a single dose of 920 cGy TBI, followed by a DLAnonidentical, unrelated marrow graft. 24 After transplantation, MMF 20 mg/kg/day was administered for 3 or 4 weeks, alone or combined with standard-dose cyclosporine for 4 weeks, or low-dose cyclosporine for 100 days. 24 In this study of mismatched grafts, MMF alone delayed the onset of acute GVHD and resulted in a modest prolongation of survival. 24 The 4-week regimen of MMF and cyclosporine (standard dose or low dose) was effective in preventing or delaying the onset of acute GVHD; slightly more than half of the dogs became long-term survivors. 24 No treatment limiting hematopoietic toxicity of MMF was observed in this study. 24 The most recently reported study by these investigators examined the effect of a conditioning regimen (from day −7 to −2) of monoclonal antibody S5 (specific for the cellular adhesion molecule CD44) 0.2 mg/kg i.v. on peripheral blood stem cell transplantation (PBSCT). 23 In this study, MHC haploidentical littermates received either the conditioning regimen and a post-graft regimen of cyclosporine plus MMF, or the conditioning regimen alone. 23 Seven of 12 dogs in the combined regimens group were surviving with stable allogeneic engraftment at a median follow-up of over 20 weeks. 23 
Preliminary clinical trials in bone marrow transplantation
Prevention of GVHD
A pilot study of MMF and cyclosporine was conducted in 14 patients following related, HLA-compatible allogeneic PBSCT. 9 A matched group of 15 comparable PBSCT Bone Marrow Transplantation recipients treated in the same institution with a prophylactic regimen of MTX and cyclosporine were used as a retrospective control. 9 The study protocol originally called for administration of MMF 1 g twice daily p.o. from day 1 to day 14. Signs of acute GVHD developed on day 12 in all patients. The treatment plan was amended to follow the regimen in the study of Yu et al 24 in DLA-nonidentical dogs, with MMF administered until day 28. The cyclosporine dose was targeted to a trough blood level of 200 to 300 ng/ml. 9 A rapid and sustained hematopoietic engraftment was achieved in all patients receiving MMF. There was no significant difference in the incidence of acute GVHD greater than or equal to grade II: 46.5% in the MMF group and 60.0% in the MTX group. Both groups were comparable in terms of acute GVHD grade or organ involvement. 9 Patient survival at a mean observation time of 13 months was also comparable; the percentage of patients alive and disease-free was 64.3% in the MMF group and 67% in the MTX group. 9 No major differences in the incidence of acute toxicities were observed, except for slightly more delayed stomatitis in patients treated with MTX and less early bladder toxicity in patients treated with MMF. 9 Mycophenolic acid trough levels were far below MPA trough levels measured in patients receiving MMF after solid organ transplantation, possibly due to the effects of pre-SCT conditioning therapies on gastrointestinal absorption. 9 The investigators recommend monitoring of MPA trough levels to maintain therapeutic concentrations and suggest oral MMF be administered only to patients with no signs of impaired alimentation due to GVHD or drug toxicity. 9 The investigators stated that before conclusions about MMF clinical efficacy could be made, dose-finding studies of intravenously administered MMF should be conducted. 9 A subsequent study conducted a dose-finding trial of GVHD prophylaxis with a post-PBSCT regimen of standarddose cyclosporine, plus MMF administered i.v. in weightadjusted doses up to 34 mg/kg/day for 21 days. 25 MMF 2 g/day was administered orally from day 22 to day 40. 25 There was only a weak correlation between the total MMF dose administered i.v. and trough blood levels of the MMF active metabolite, MPA. 25 Two of 15 patients discontinued MMF therapy due to GI side-effects. 25 A separate group of investigators at the Clinic for Bone Marrow Transplantation and Hematology/Oncology in Odar-Obestein, Germany conducted similar pilot studies of MMF for the prophylaxis of GVHD. 10, 26 In the first study, MMF 1 g/day p.o. was initiated on day 10 post transplantation in eight recipients of related or unrelated, matched or mismatched SCT or PBSCT. 26 Less than half (3/8) developed acute GVHD of grade 0-III. 26 In addition, this study reported a significant reduction in the requirement for prednisolone therapy 26 (see Figure 1 ). Intravenous administration of MMF, 2 g/day, was also examined in a pilot study that compared response to a postgraft regimen of cyclosporine, prednisolone and MMF vs the response to cyclosporine, prednisolone, and intermittent, tapered MTX (starting at 15 mg/m 2 /day) in a matched, historical control. 10 The efficacy of the MMF i.v. regimen was comparable to that seen with the MTX-containing regimen. Acute GVHD occurred in eight of 16 patients receiv- The steroid-sparing effect of MMF in 30 recipients of either a related, HLA-matched or -mismatched, or an unrelated, matched SCT graft () compared to the percent mean prednisolone dose administered to a matched, historical control group (í) (*P Ͻ 0.01). Each point represents a percent of prednisolone therapy administered over time, where 100% is a mean of 55 Ϯ 15 mg for patients with acute GVHD, and 15 Ϯ 5 mg for patients with chronic GVHD. 26 ing MMF (three grade III-IV and five grade I-II), and nine of 16 patients in the historical control group (four grade III-IV and five grade I-II). 10 The incidence of mucositis (WHO grade III-IV) was significantly greater in the MTXregimen group (P Ͻ 0.05). 10 A third group of investigators conducted two pilot clinical trials employing the prophylactic regimen of nonmyeloablative conditioning combined with MMF plus cyclosporine post graft, as tested in canines. 27, 28 The first of these studies was conducted in 44 older patients (median age 56 years; age range 31 to 72 years) with a hematologic malignancy treated with an HLA-identical PBSCT. 27 The conditioning regimen was 200 cGy TBI pre-graft and the post-graft regimen was short-term (35 or 56 days) MMF plus cyclosporine. 27 Donor lymphocytes were given post transplant to achieve persistent donor chimerism and/or eradication of the malignancy through graft-versus-tumor effect. By 2 months, the 42 evaluable patients had achieved stable and persistent donor engraftment. 27 At a median follow-up of 190 days, 39% had developed acute GVHD grades II-IV. 27 The acute toxicities commonly associated with allografting were markedly reduced even in the older patients of this trial. 27 Larger studies are needed to determine how effective this approach is for disease treatment.
These investigators also examined the effects of modifying the prophylactic protocol by adding fludarabine 30 mg/m 2 /day on days −4, −3, and −2 to the conditioning regimen in 11 patients (age range 40 to 61 years) with hematologic malignancies. 28 Nine patients received HLA-matched, unrelated SCT; two patients received a one-allele mismatched, unrelated SCT. All 10 of the evaluable patients experienced engraftment; three patients developed aGVHD, which was fatal in one patient. 28 A summary of trials on the use of MMF in the prevention of GVHD is seen in Table 1 .
Treatment of GVHD
In recent years the investigators in the BMT clinic in OdarObestein, Germany have reported the results of an ongoing, open-label trial of MMF for the treatment of acute or chronic GVHD. 11, 29, 30 In each report, recipients of a stem cell graft received GVHD prophylaxis with cyclosporine (5 mg/kg/day i.v.) started on day −3, plus MTX (15 mg/m 2 ) on day +1 and 10 mg/m 2 on days +3 and +6, and prednisolone 0.5 mg/kg/day from day +7, increasing to 1.0 mg/kg/day on day +14. 11, 29 Acute GVHD was treated with MMF 250 mg p.o. four times a day, increased to 2 g/day; prednisolone 1 mg/kg/day for 14 days and then tapered; and cyclosporine targeted to trough blood levels of 200 to 300 mol/ml. 11, 29 For severe acute GVHD, the dose of MMF was increased to 2 to 3 g/day. 30 This immunosuppressive regimen was modified to a starting dose of MMF 2 g/day for the treatment of chronic GVHD. 11, 29 Treatment regimens administered in the historical control group did not include MMF, but otherwise corresponded to study regimens.
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Although it is not clear if there is an overlap of patients reported in these studies, more patients were included in the latter study. A one-grade improvement was seen in 15 of the 21 patients in the MMF treatment group with acute GVHD (71%) compared to six of the 14 patients with acute GVHD in the control group (43%; P = 0.023). 11 In patients with chronic GVHD, the response was moderate improvement in four of the eight patients in the MMF treatment group with limited chronic GVHD and one of five patients with limited chronic GVHD in the control group.
When analyzed by acute GVHD symptoms, 17 of the 18 patients in the MMF group with skin involvement (stages 1-4) experienced improvement, compared with 10 of the 13 control patients. 11 There was a similar difference in the response of patients with GI involvement (stages 1-4). Four of the five patients with GI acute GVHD in the MMF group improved, while improvement was reported in four of the 10 control patients with GI acute GVHD. 11 Slightly more than half of the patients in either treatment group with liver acute GVHD (stages 1-4) improved (five of eight patients in the MMF group and five of nine patients in the control group).
The most common adverse experience in either treatment group was hematologic. 11 The incidence of leukopenia was comparable in both treatment groups: six of 30 patients treated with the MMF-containing regimen vs four of 21 patients in the control group. 11 Similarly, the incidence of thrombocytopenia was not significantly different: five of 30 patients in the MMF group vs eight of 21 patients in the control group. 11 Anemia occurred in more patients (four of 30 patients) treated with MMF than the control patients (one of 21). 11 In both treatment groups, adverse GI events included diarrhea, nausea, and vomiting. No nephrotoxicity or hepatotoxicity was observed in this study. the matched, historical control group, the MMF regimen resulted in a significant reduction in the dose of prednisolone that was required (P Ͻ 0.01) 11 (see Figure 1) . In a smaller, uncontrolled study of eight patients with severe acute GVHD reported by the above-mentioned center, MMF demonstrated encouraging clinical improvement, especially in patients without acute GVHD of the gut. 30 All three patients with skin acute GVHD (grade III-IV) experienced improvement in GVHD symptoms. However, only one of four patients with gut GVHD (grade III-IV) improved, and the one patient with both liver and gut acute GVHD (grade III-IV) did not improve, possibly due to poor absorption. 30 The mean MPA steady-state level in the five patients with gut GVHD (1.03 mg/l) was lower than it was in the three patients with skin GVHD (1.92 mg/l). 30 These investigators recently issued a 3-year summary of the efficacy and safety of MMF in acute and chronic GVHD in their center. 31 During this period, 36 patients with acute GVHD and 12 patients with chronic GVHD were treated with cyclosporine, prednisolone, and 2 g/day MMF. A matched control group (14 with acute GVHD and seven with chronic GVHD) was treated with cyclosporine and prednisolone only. 31 Among patients treated with MMF, overall grade improvement was achieved by 72% of patients (26/36) with acute GVHD, compared to 29% of patients (5/14) in the control group (P Ͻ 0.02). 31 When analyzed by organ involvement, improvement among patients treated with MMF was significantly greater than with the control regimen in patients with skin acute GVHD (25/28; P Ͻ 0.01) or liver acute GVHD (9/12; P Ͻ 0.02). 31 Moderate improvement with the MMF regimen was experienced in 50% of patients (6/12) with limited chronic GVHD. 31 The most common hematologic adverse effects were leukopenia (n = 9), anemia (n = 9), and thrombocytopenia (n = 8). 31 None were severe or treatment limiting. 31 In two small studies, the patient population included patients with either acute or chronic GVHD. 32, 33 One evaluBone Marrow Transplantation ated seven patients with severe acute GVHD (five grade III, two grade IV) whose condition had become resistant to steroid therapy. 32 The median time to onset of salvage therapy was 43 days after bone marrow transplantation. 32 Treatment with MMF 2 g/day for adults or 600 mg/m 2 for children was continued for a median duration of 25 days. 32 Four of the seven patients (58%) required a 50% to 75% reduction in MMF dose; two of the seven (29%) experienced a complete or partial response. 32 Twelve patients with refractory GVHD were also evaluated. MMF was administered for a median of 169 days to patients with chronic GVHD. 32 A complete or partial response was seen in four of the 12 patients. At 8 weeks, nearly half of the patients experienced leukopenia or thrombocytopenia, and 18% had an abnormal transaminase (AST) level. 32 The other study included two patients with high-grade acute GVHD (grades III-IV) who had failed steroid and/or ATG therapy. 33 Salvage therapy was MMF 1 g/day plus cyclosporine. At a short-term follow-up, both patients were responding to therapy without hematologic or metabolic side effects. 33 In this study, eight patients had chronic GVHD (two limited, six extensive). 33 Following salvage therapy with MMF for a median of 120 days, the two patients with limited GVHD were responding, but none of the six patients with extensive GVHD responded to therapy. 33 A phase II trial of MMF in refractory chronic GVHD was performed on patients treated at the Johns Hopkins Oncology Center between January 1997 and December 1997. 12 Retrospective analysis evaluated the response of 26 patients who flared on a post-SCT regimen of at least cyclosporine or tacrolimus and prednisone. 12 Current treatments were discontinued and replaced with a salvage regimen of MMF 1 g p.o. twice daily, plus tacrolimus 1 mg p.o. twice daily, dose-adjusted to a target trough level of 5 to 10 ng/ml. 12 An overall objective response rate was achieved by 46%; two patients had a complete response and 10 patients
Discussion
The rationale for testing MMF as an immunosuppressant in the bone marrow transplantation setting is derived from preclinical findings in models of GVHD, as well as clinical results with MMF in solid organ allograft recipients. Clinical experience in solid organ allograft recipients has shown the potential of MMF to decrease the incidence and severity of acute rejection episodes. The safety profile of MMF in this setting is acceptable and does not overlap with the significant toxicities of commonly used immunosuppressant agents.
The small, preliminary trials of MMF to treat GVHD reviewed here have significant limitations. The size and duration of the trials were limited. Clinical features of the study participants were not uniform, nor was the preconditioning therapy, nor the method of stem cell transfer. Nevertheless, encouraging results were seen when MMF was used in a minimally myelosuppressive conditioning regimen, and encouraging improvement was seen in severe and refractory GVHD. In addition, a significant steroidsparing effect was seen in the treatment of GVHD. However, the adverse events associated with MMF that were acceptable in solid organ allograft recipients may be more of a problem in the SCT setting, because they can mimic the symptoms of GVHD. 23 These findings suggest that further investigation is warranted. Larger, well-controlled clinical trials are needed to determine the optimum dose and route of MMF administration for GVHD, as well as the comparative safety and efficacy of MMF-containing regimens. A significant concern for study in this setting is to determine the extent to which MMF contributes to adverse events that overlap with the symptoms of GVHD. One of the most promising areas involves the use of MMF in post-graft immunosuppressive regimens after non-myeloablative TBI.
